0000950123-18-001663.txt : 20180213
0000950123-18-001663.hdr.sgml : 20180213
20180213111417
ACCESSION NUMBER: 0000950123-18-001663
CONFORMED SUBMISSION TYPE: 13F-HR
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20171231
FILED AS OF DATE: 20180213
DATE AS OF CHANGE: 20180213
EFFECTIVENESS DATE: 20180213
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Biomark Capital Management Co. LLC
CENTRAL INDEX KEY: 0001667082
IRS NUMBER: 463904521
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 13F-HR
SEC ACT: 1934 Act
SEC FILE NUMBER: 028-17353
FILM NUMBER: 18600785
BUSINESS ADDRESS:
STREET 1: 537 STEAMBOAT RD., SUITE 200
CITY: GREENWICH
STATE: CT
ZIP: 06830
BUSINESS PHONE: 203-769-2345
MAIL ADDRESS:
STREET 1: 537 STEAMBOAT RD., SUITE 200
CITY: GREENWICH
STATE: CT
ZIP: 06830
13F-HR
1
primary_doc.xml
13F-HR
LIVE
false
true
false
0001667082
XXXXXXXX
12-31-2017
12-31-2017
Biomark Capital Management Co. LLC
537 STEAMBOAT RD., SUITE 200
Greenwich
CT
06830
13F HOLDINGS REPORT
028-17353
Y
The filing of this report shall not be deemed an admission, for purposes of Section 13(f), 13(d), 13(g), or 16(a) under the Securities Exchange Act of 1934, as amended, and the rules thereunder, or for any other purpose, that the Reporting Manager or any other person (including Other Managers or Other Included Managers named herein) is the beneficial owner of any securities.
Biomark Capital Management Co. LLC, a Delaware limited liability company (the "Management Company"), is an institutional investment manager which, for the purposes of Section 13(f) of the Securities Exchange Act of 1934 and the rules promulgated thereunder ("Section 13(f)"), exercises investment discretion with respect to certain securities positions held directly and indirectly by Biomark Capital Fund IV LP, a Delaware limited partnership (the "Fund"). David S. Wetherell, an individual ("Wetherell") and Biomark Capital Fund IV GP LLC, a Delaware limited liability company (the "General Partner"), may each be deemed to exercise investment discretion over the securities reported on this Form 13F for purposes of Section 13(f). Certain of the security positions reported by the Management Company are also being reported by Wetherell and the General Partner. Also, 99,384 shares of common stock of Juno Therapeutics, Inc. reported by the Management Company are held by a majority owned portfolio company of the Fund. Each of the Management Company, the General Partner and Wetherell disclaims beneficial ownership of the shares reported on this Form 13F by the Management Company except to the extent of any pecuniary interest therein.
David S. Wetherell
Manager
(203) 769-2345
/s/ David S. Wetherell
Boston
MA
02-13-2018
2
3
89831
false
1
28-17351
Biomark Capital Fund IV GP LLC
2
28-17354
David S. Wetherell
INFORMATION TABLE
2
form13fInfoTable.xml
INFORMATION TABLE FOR FORM 13F
JUNO THERAPEUTICS, INC.
COM
48205A109
85211
1864174
SH
OTR
1,2
1764790
99384
0
MABVAX THERAPEUTICS HOLDINGS, INC.
COM NEW
55414P504
19
26708
SH
OTR
1,2
26708
0
0
ADMA BIOLOGICS, INC.
COM
000899104
4601
1433304
SH
OTR
1,2
1433304
0
0